Neuropsychiatric Disease and Treatment
ISSN 1176-6328 · Dove Medical Press · United Kingdom · active 1971–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Responding time
Turnaround figures are indicative, not a guarantee: DOAJ values are self-reported by the journal (average weeks, submission to publication); library estimates are medians of the received/accepted dates printed in papers we hold. Editorial times vary by article type and season — confirm on the journal’s own site.
Indexing & access
Access status: gold. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Neuropsychiatric Disease and Treatment a predatory journal?
Our screening does not flag Neuropsychiatric Disease and Treatment. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.
Is Neuropsychiatric Disease and Treatment indexed in Scopus or Web of Science?
Per our venue index, Neuropsychiatric Disease and Treatment appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Neuropsychiatric Disease and Treatment?
Papers in Neuropsychiatric Disease and Treatment are cited about 2.7 times each within two years of publication, and Scimago places it in Q2, with an h-index of 120. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Neuropsychiatric Disease and Treatment (Q1, Q2, Q3, or Q4)?
Scimago places Neuropsychiatric Disease and Treatment in Q2 for its subject category. Quartiles split the journals in a field into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Neuropsychiatric Disease and Treatment is cited about 2.7 times per paper over two years, with an h-index of 120. A journal is ranked per subject category, so one spanning several fields can sit in different quartiles depending on the category.
What is the Web of Science (JCR) quartile of Neuropsychiatric Disease and Treatment?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Neuropsychiatric Disease and Treatment. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Neuropsychiatric Disease and Treatment open access?
Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
How long does Neuropsychiatric Disease and Treatment take to publish a paper?
Submission to publication for Neuropsychiatric Disease and Treatment takes about ~16 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Neuropsychiatric Disease and Treatment.